Regeneron Pharmaceuticals Director Michael S. Brown Unloads 3,000 Shares (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN) Director Michael S. Brown sold 3,000 shares of the stock on the open market in a transaction dated Friday, August 15th. The shares were sold at an average price of $349.20, for a total value of $1,047,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.24% on Monday, hitting $349.46. 509,980 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a one year low of $227.64 and a one year high of $352.49. The stock’s 50-day moving average is $316. and its 200-day moving average is $308.5. The company has a market cap of $35.082 billion and a P/E ratio of 99.21.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings data on Tuesday, August 5th. The company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the previous year, the company posted $1.73 earnings per share. The company’s quarterly revenue was up 45.4% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $10.14 EPS for the current fiscal year.
A number of analysts have recently weighed in on REGN shares. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Regeneron Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $345.94.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.